NovaBay Pharmaceuticals Inc (AMEX:NBY)
$ 0.1186 -0.0014 (-1.17%) Market Cap: 4.49 Mil Enterprise Value: 6.63 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 41/100

NovaBay Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript

Jul 14, 2021 / 08:30PM GMT
Release Date Price: $21.04 (-0.97%)
Jeff Cohen
Ladenburg Thalmann - Analyst

Good afternoon. This is Jeff Cohen Destiny Hance of Ladenburg Thalmann. Thanks for joining us. Next up we have NovaBay Pharmaceuticals. With us today from NovaBay is Justin Hall, President and CEO, General Counsel, Chief Compliance Officer, Corporate Secretary and Director; and with him is Andrew Jones, who is CFO and Treasurer of the Company. Thank you both for joining us. And Justin, I will give you the floor.

Justin Hall
NovaBay Pharmaceuticals, Inc. - CEO

All right. Thanks, Jeff. So I am here with Andrew Jones, our CFO. Yes, happy to introduce NovaBay to everybody who is listening. So the NovaBay story really starts with Avenova. And Avenova is the number one antimicrobial lid and lash spray in the US dry-eye market. So we launched this commercially in 2016 to ophthalmologists and optometrists for the dry-eye and blepharitis space.

And so over the past five years during our commercialization strategy, we have developed several sales channels. The first being that prescription-only version of Avenova being

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot